Intuitive surgical systems were used in an average of over 10,000 procedures a day.
Intuitive Surgical (ISRG) reported Q3 2026 revenue of $3.05B, up 22% YoY. Procedures grew 15% YoY, with da Vinci systems up 14% and Ion up 31%. GAAP net income was $523M, or $1.49 per share, including a $450M litigation charge. Non-GAAP net income was $1.05B, or $3.00 per share. The company placed 546 da Vinci and 56 Ion systems. ISRG expects 14-15% procedure growth for 2026 and non-GAAP gross margin of 68.7-69.3%.
How this was made
The 30-second read
Why it matters
The mixed earnings outcome may lead to modest price volatility as investors digest both strong top‑line growth and lower profitability.
Market read
The release provides fresh earnings data and guidance that can affect ISRG and peers in the medical device space.
What to watch
Tariff impact on margins and the pace of system placements may limit future profitability.
Background
Intuitive Surgical reported its Q3 2026 financial results, highlighting system placements, procedure growth, and a large share repurchase.
Ticker impact
Q3 2026 earnings release with revenue up 22% to $3.05B and GAAP net income down 26% to $523M, plus a $2.94B share repurchase and $450M litigation settlement.
likely pressure as investors weigh lower earnings against strong revenue growth and sizable buyback.
The earnings beat on revenue but miss on profit, combined with a $2.94B repurchase, creates mixed signals that may temper price gains.
Market effects
reinforces growth narrative for surgical robotics and minimally invasive device sector.
supports US healthcare equipment market sentiment with higher procedure volumes.
signals continued global demand for robotic surgery platforms.
Counterpoint
The settlement charge and declining GAAP profit could outweigh revenue growth, prompting a short‑term pullback.
Key entities
- CompanyIntuitive Surgical
US‑listed maker of da Vinci and Ion surgical systems.
